Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz Sells 6,500 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Voyager Therapeutics Stock Up 2.2 %

Shares of VYGR opened at $5.91 on Friday. The company has a 50 day moving average of $6.39 and a 200-day moving average of $7.02. The stock has a market capitalization of $322.84 million, a P/E ratio of 8.32 and a beta of 0.90. Voyager Therapeutics, Inc. has a twelve month low of $5.19 and a twelve month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the company posted ($0.59) earnings per share. On average, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. China Universal Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Voyager Therapeutics in the second quarter valued at approximately $85,000. Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics during the third quarter worth approximately $74,000. Victory Capital Management Inc. lifted its holdings in Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in Voyager Therapeutics in the 2nd quarter valued at $128,000. 48.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

VYGR has been the subject of several research reports. Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. Wedbush assumed coverage on Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.